Data Analytics for Pharmaceutical Companies in the UK: What Good Actually Looks Like

Walk into the commercial function of almost any pharmaceutical company operating in the UK and you will find the same landscape: an IQVIA subscription somewhere, a CRM full of half-standardised call notes, a finance system with the "real" numbers, a SharePoint of monthly decks, and at least one heroic spreadsheet held together by a single analyst everyone is terrified will resign.

Every one of those assets cost real money. The problem is never the data. It is that nothing joins up — so every question becomes a project, and every month starts with the same ritual of rebuilding the same numbers.

The UK data landscape is unusually rich — and unusually fragmented

UK-based teams actually have more to work with than most markets:

• Market data — IQVIA sell-in and sell-out feeds, the backbone of share tracking, each with their own product mappings and revision cycles.
• Internal data — sales, tender wins and losses, pricing, CRM activity, targeting lists.
• Public NHS data — an asset many teams underuse. Primary-care prescribing is published monthly and explorable through tools like OpenPrescribing^[1]; hospital medicines consumption is published as open data too. For molecule-level questions — who is prescribing, where, how fast is a switch happening — this is remarkable, free intelligence.

The catch: these sources disagree with each other by design. Different product hierarchies, different geographies, different lags. Analytics that ignores the reconciliation problem produces dashboards that quietly contradict each other — and the first time two numbers disagree in a leadership meeting, trust in all of them dies.

What "good" looks like

After building these platforms inside and for pharma companies, the pattern that works has a consistent shape:

1. One governed data model, before any dashboards

Product mappings (molecule → brand → pack), geography mappings and calendar alignment are decided once, centrally, and every downstream view inherits them. This is unglamorous work. It is also 60% of the value, because it is the thing that makes every number agree with every other number.

2. Automated refresh, not monthly assembly

If a person has to assemble the numbers, the numbers are already old. Pipelines land the new IQVIA extract, the CRM export and the finance actuals on schedule; validation checks run automatically; dashboards refresh themselves. The team's time moves from production to interpretation — which is the only part that was ever valuable.

3. Views organised by decision, not by source

Nobody makes a decision "in IQVIA". They make territory decisions, brand decisions, access decisions. Good pharma commercial analytics organises around those: a territory view that blends activity and outcome, a brand view that splits market growth from share movement, an access view that puts formulary and tender status next to the volume they drive.

4. An AI layer on top — grounded in the governed data

This is the newest layer and the one changing fastest. With the foundation in place, an AI layer over the warehouse lets any user ask a plain-English question — "how did the launch track against plan in the North West last quarter?" — and get an answer drawn from the same governed model as every dashboard. Without the foundation, the same AI confidently synthesises nonsense from inconsistent sources. The order of operations matters: data first, then AI — a point we've made at length in our guide to AI in the pharmaceutical industry.

The failure modes to avoid

Three patterns kill these initiatives reliably: buying dashboards before fixing the data model (pretty views of contradictory numbers); an eighteen-month "data transformation programme" that ships nothing until month seventeen (start with one decision, one set of sources, live in weeks); and per-seat licensed platforms that hold your own numbers hostage (own the warehouse, own the code).

The test of a commercial analytics platform is brutally simple: when two executives disagree about a number, do they open the platform to settle it — or open Excel to rebuild it?

If your team is still in the rebuild-it-monthly world, the path out is shorter than it looks. Book a discovery call and tell us which numbers you fight with most.